FDA Grants Rare Pediatric Disease Designation to Omeros MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
| OMER Stock | USD 9.33 0.15 1.63% |
Slightly above 56% of all Omeros' retail investors are looking to take a long position. The analysis of overall sentiment of trading Omeros stock suggests that some investors are interested at this time. Omeros' investing sentiment overview a quick insight into current market opportunities from investing in Omeros. Many technical investors use Omeros stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Omeros |
Omeros Corporation today announced that zaltenibart has received rare pediatric disease designation from the U.S. Food and Drug Administratio
Read at businesswire.com
 |
Omeros Fundamental Analysis
We analyze Omeros' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Omeros using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Omeros based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Shares Owned By Insiders
Shares Owned By Insiders Comparative Analysis
Omeros is currently under evaluation in shares owned by insiders category among its peers. Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
Omeros Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Omeros stock to make a market-neutral strategy. Peer analysis of Omeros could also be used in its relative valuation, which is a method of valuing Omeros by comparing valuation metrics with similar companies.
Peers
Omeros Related Equities
| ENTA | Enanta Pharmaceuticals | 8.25 | ||||
| DSGN | Design Therapeutics | 6.75 | ||||
| AKRO | Akero Therapeutics | 4.71 | ||||
| LYEL | Lyell Immunopharma | 3.57 | ||||
| MIRM | Mirum Pharmaceuticals | 2.44 | ||||
| CRNX | Crinetics Pharmaceuticals | 2.38 | ||||
| RNA | Avidity Biosciences | 2.23 | ||||
| PASG | Passage Bio | 1.69 | ||||
| DAWN | Day One | 1.13 | ||||
| RVMD | Revolution Medicines | 0.98 | ||||
| CNTB | Connect Biopharma | 0.96 | ||||
| PTGX | Protagonist Therapeutics | 0.77 | ||||
| LGND | Ligand Pharmaceuticals | 0.73 | ||||
| FOLD | Amicus Therapeutics | 0.53 | ||||
| STOK | Stoke Therapeutics | 1.06 | ||||
| BMEA | Biomea Fusion | 1.97 | ||||
| GOSS | Gossamer Bio | 4.00 | ||||
| ORIC | Oric Pharmaceuticals | 4.58 | ||||
| ARQT | Arcutis Biotherapeutics | 7.78 |
Additional Tools for Omeros Stock Analysis
When running Omeros' price analysis, check to measure Omeros' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Omeros is operating at the current time. Most of Omeros' value examination focuses on studying past and present price action to predict the probability of Omeros' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Omeros' price. Additionally, you may evaluate how the addition of Omeros to your portfolios can decrease your overall portfolio volatility.